Iron Triangle Partners LP Buys New Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Iron Triangle Partners LP bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 65,409 shares of the biopharmaceutical company’s stock, valued at approximately $17,662,000. Alnylam Pharmaceuticals comprises approximately 2.8% of Iron Triangle Partners LP’s portfolio, making the stock its 16th largest holding. Iron Triangle Partners LP owned 0.05% of Alnylam Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently bought and sold shares of ALNY. Brighton Jones LLC purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $243,000. NewEdge Advisors LLC raised its holdings in shares of Alnylam Pharmaceuticals by 97,200.0% in the fourth quarter. NewEdge Advisors LLC now owns 973 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 972 shares during the last quarter. Stifel Financial Corp raised its holdings in shares of Alnylam Pharmaceuticals by 71.8% in the fourth quarter. Stifel Financial Corp now owns 10,017 shares of the biopharmaceutical company’s stock worth $2,357,000 after buying an additional 4,187 shares during the last quarter. Integrated Wealth Concepts LLC raised its holdings in shares of Alnylam Pharmaceuticals by 7.5% in the fourth quarter. Integrated Wealth Concepts LLC now owns 2,512 shares of the biopharmaceutical company’s stock worth $591,000 after buying an additional 176 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC raised its holdings in shares of Alnylam Pharmaceuticals by 8.3% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 2,633 shares of the biopharmaceutical company’s stock worth $620,000 after buying an additional 202 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 0.4%

ALNY stock opened at $452.33 on Friday. The firm has a market cap of $59.29 billion, a PE ratio of -183.13 and a beta of 0.25. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The firm’s fifty day moving average is $371.83 and its 200 day moving average is $301.51. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $469.81.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. The company had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm’s revenue was up 17.3% on a year-over-year basis. During the same quarter last year, the business earned ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on ALNY shares. Raymond James Financial started coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, July 30th. They issued an “outperform” rating and a $370.00 price target for the company. Truist Financial started coverage on shares of Alnylam Pharmaceuticals in a report on Monday, July 21st. They issued a “buy” rating and a $385.00 price target for the company. JPMorgan Chase & Co. raised their price target on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an “overweight” rating in a report on Wednesday, August 6th. Morgan Stanley raised their price target on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an “equal weight” rating in a report on Friday, August 1st. Finally, Oppenheimer raised shares of Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 price target for the company in a report on Monday, August 4th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $405.33.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director Michael W. Bonney sold 11,250 shares of the firm’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the sale, the director owned 16,804 shares in the company, valued at approximately $7,561,800. This trade represents a 40.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jeffrey V. Poulton sold 2,274 shares of the firm’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $453.27, for a total transaction of $1,030,735.98. Following the sale, the executive vice president owned 50,121 shares in the company, valued at approximately $22,718,345.67. This represents a 4.34% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 76,891 shares of company stock valued at $31,456,338 in the last quarter. 1.50% of the stock is currently owned by insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.